Zentalis Pharmaceuticals Inc (ZNTL) Stock Price, Quote & News

Latest News on ZNTL

Apr 23, 2025, 4:05 PM EDT - 4 days ago

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

Apr 1, 2025, 5:30 PM EDT - 26 days ago

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 26, 2025, 4:05 PM EDT - 4 weeks ago

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Mar 25, 2025, 4:40 PM EDT - 4 weeks ago

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 15, 2025, 11:25 AM EDT - 6 weeks ago

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Mar 3, 2025, 8:00 AM EST - 2 months ago

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Feb 24, 2025, 4:05 PM EST - 2 months ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Feb 3, 2025, 5:42 PM EST - 2 months ago

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 29, 2025, 7:00 AM EST - 3 months ago

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Jan 28, 2025, 4:05 PM EST - 3 months ago

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Jan 9, 2025, 7:00 AM EST - 3 months ago

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Dec 12, 2024, 7:00 AM EST - 4 months ago

Zentalis Pharmaceuticals Announces Key Management Appointments

Nov 21, 2024, 1:14 PM EST - 5 months ago

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Oct 7, 2024, 2:03 PM EDT - 7 months ago

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

Sep 16, 2024, 9:00 AM EDT - 8 months ago

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers

Sep 16, 2024, 7:00 AM EDT - 8 months ago

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Sep 9, 2024, 7:00 AM EDT - 8 months ago

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Aug 19, 2024, 4:55 PM EDT - 8 months ago

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

Aug 19, 2024, 11:00 AM EDT - 9 months ago

Investors In Zentalis Pharmaceuticals Inc Encouraged To Participate In Fraud Investigation With The Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 9 months ago

Shareholders With Losses In Zentalis Pharmaceuticals Inc Invited To Join Fraud Investigation With Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 9 months ago

Zentalis Pharmaceuticals Inc Investors Asked To Partake In Fraud Investigation With Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 9 months ago

Zentalis Pharmaceuticals Inc Stockholders Invited To Join In Fraud Investigation With Schall Law Firm

Aug 15, 2024, 4:00 PM EDT - 9 months ago

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Aug 15, 2024, 11:00 AM EDT - 9 months ago

Zentalis Pharmaceuticals Inc Investors Welcome To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 9 months ago

Zentalis Pharmaceuticals Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 1:00 AM EDT - 9 months ago

Zentalis Pharmaceuticals Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Aug 12, 2024, 11:15 PM EDT - 9 months ago

Zentalis Pharmaceuticals Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Aug 9, 2024, 9:15 PM EDT - 9 months ago

Zentalis Pharmaceuticals Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm

Aug 9, 2024, 7:00 AM EDT - 9 months ago

Market Cap	84.02M
Revenue (ttm)	67.43M
Net Income (ttm)	-165.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-245.94%
Debt to Equity Ratio	0.00

Volume	545,600
Avg Vol	921,574
Day's Range	N/A - N/A
Shares Out	71.81M
Stochastic %K	64%
Beta	1.80
Analysts	Sell
Price Target	$5.97